Core Insights - Phathom Pharmaceuticals reported a quarterly loss of $0.15 per share, outperforming the Zacks Consensus Estimate of a loss of $0.30, and showing improvement from a loss of $1.32 per share a year ago, resulting in an earnings surprise of +50.00% [1] - The company achieved revenues of $49.5 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 0.64% and significantly up from $16.35 million in the same quarter last year [2] - Phathom Pharmaceuticals' stock has increased by approximately 66.6% since the beginning of the year, compared to a 17.2% gain in the S&P 500 [3] Earnings Outlook - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is -$0.17 on revenues of $55.35 million, and for the current fiscal year, it is -$2.31 on revenues of $172.56 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Phathom Pharmaceuticals belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors or through tools like the Zacks Rank [5][6]

Core Insights - Tradeweb Markets (TW) reported quarterly earnings of $0.87 per share, exceeding the Zacks Consensus Estimate of $0.83 per share, and showing an increase from $0.75 per share a year ago, resulting in an earnings surprise of +4.82% [1] - The company achieved revenues of $508.6 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.05% and up from $448.92 million year-over-year [2] - Tradeweb has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Earnings Outlook - The sustainability of Tradeweb's stock price movement will largely depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.84, with projected revenues of $514.72 million, and for the current fiscal year, the estimate is $3.40 on $2.04 billion in revenues [7] Industry Context - The Financial - Investment Bank industry, to which Tradeweb belongs, is currently ranked in the top 11% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - The correlation between near-term stock movements and earnings estimate revisions suggests that investors should monitor these revisions closely [5]

Company Performance - 1-800-Flowers.com reported a quarterly loss of $0.83 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.59, and compared to a loss of $0.51 per share a year ago, indicating a significant earnings surprise of -40.68% [1] - The company posted revenues of $215.2 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 1.45%, and down from $242.09 million in the same quarter last year [2] - Over the last four quarters, 1-800-Flowers.com has not surpassed consensus EPS estimates and has topped revenue estimates only once [2] Stock Performance - Shares of 1-800-Flowers.com have declined approximately 57.3% since the beginning of the year, contrasting with the S&P 500's gain of 17.2% [3] - The current Zacks Rank for the stock is 4 (Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.89 on revenues of $725.34 million, while for the current fiscal year, the estimate is -$0.62 on revenues of $1.59 billion [7] - The trend of estimate revisions for 1-800-Flowers.com was unfavorable prior to the earnings release, which may impact future stock movements [6] Industry Context - The Retail - Mail Order industry, to which 1-800-Flowers.com belongs, is currently ranked in the bottom 16% of over 250 Zacks industries, suggesting a challenging environment for the company [8]

Core Insights - CSW Industrials reported quarterly earnings of $2.96 per share, exceeding the Zacks Consensus Estimate of $2.73 per share, and showing an increase from $2.26 per share a year ago, resulting in an earnings surprise of +8.42% [1] - The company achieved revenues of $276.95 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.19% and up from $227.93 million year-over-year [2] Earnings Performance - CSW Industrials has surpassed consensus EPS estimates in all four of the last quarters [2] - The company has topped consensus revenue estimates two times over the last four quarters [2] Stock Performance - CSW Industrials shares have declined approximately 30.8% since the beginning of the year, contrasting with the S&P 500's gain of 17.2% [3] Future Outlook - The company's earnings outlook will be crucial for assessing future stock performance, including current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is $2.36 on revenues of $252 million, and for the current fiscal year, it is $10.35 on revenues of $1.05 billion [7] Industry Context - The Chemical - Specialty industry, to which CSW Industrials belongs, is currently ranked in the bottom 34% of over 250 Zacks industries, indicating potential challenges ahead [8]

Group 1: Earnings Performance - Cigna reported quarterly earnings of $7.83 per share, exceeding the Zacks Consensus Estimate of $7.7 per share, and up from $7.51 per share a year ago, representing an earnings surprise of +1.69% [1] - The company posted revenues of $69.57 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.59%, compared to $63.7 billion in the same quarter last year [2] Group 2: Stock Performance and Outlook - Cigna shares have increased by approximately 8.3% since the beginning of the year, while the S&P 500 has gained 17.2% [3] - The current consensus EPS estimate for the upcoming quarter is $8.04 on revenues of $67.81 billion, and for the current fiscal year, it is $29.69 on revenues of $267.39 billion [7] Group 3: Industry Context - The Medical - HMOs industry, to which Cigna belongs, is currently ranked in the bottom 35% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - The Joint Corp., another company in the same industry, is expected to report a quarterly loss of $0.01 per share, reflecting a year-over-year change of -125%, with revenues anticipated to be $13.27 million, down 56.1% from the previous year [9]

Core Insights - Methanex reported quarterly earnings of $0.06 per share, significantly missing the Zacks Consensus Estimate of $0.51 per share, and down from $1.21 per share a year ago, representing an earnings surprise of -88.24% [1] - The company posted revenues of $927 million for the quarter ended September 2025, which was 4.83% below the Zacks Consensus Estimate and a decrease from $935 million year-over-year [2] - Methanex shares have declined approximately 30.9% year-to-date, contrasting with the S&P 500's gain of 17.2% [3] Earnings Outlook - The future performance of Methanex's stock will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.88 on revenues of $1.07 billion, while for the current fiscal year, the estimate is $3.66 on revenues of $3.73 billion [7] Industry Context - The Chemical - Diversified industry, to which Methanex belongs, is currently ranked in the bottom 7% of over 250 Zacks industries, indicating a challenging environment [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Methanex's stock performance [5][6]

Core Insights - Guardant Health reported a quarterly loss of $0.39 per share, better than the Zacks Consensus Estimate of a loss of $0.48, and improved from a loss of $0.45 per share a year ago, resulting in an earnings surprise of +18.75% [1] - The company achieved revenues of $265.2 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 13.05% and showing a significant increase from $191.48 million in the same quarter last year [2] - Guardant Health's stock has increased by approximately 127.8% since the beginning of the year, outperforming the S&P 500's gain of 17.2% [3] Financial Performance - Over the last four quarters, Guardant Health has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $251.41 million, and for the current fiscal year, it is -$1.84 on revenues of $921.37 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Guardant Health belongs, is currently ranked in the top 37% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Murphy USA reported quarterly earnings of $7.25 per share, exceeding the Zacks Consensus Estimate of $6.6 per share, and showing a slight increase from $7.2 per share a year ago, resulting in an earnings surprise of +9.85% [1] - The company generated revenues of $5.11 billion for the quarter ended September 2025, which fell short of the Zacks Consensus Estimate by 0.44% and decreased from $5.24 billion year-over-year [2] - Murphy USA has surpassed consensus EPS estimates three times over the last four quarters but has not beaten revenue estimates during the same period [2] Future Outlook - The sustainability of the stock's price movement will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $6.46 on revenues of $4.94 billion, while for the current fiscal year, it is $23.18 on revenues of $19.61 billion [7] - The estimate revisions trend for Murphy USA was unfavorable prior to the earnings release, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [6] Industry Context - The Retail - Convenience Stores industry, to which Murphy USA belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a relatively strong position within the market [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Bio-Rad Laboratories reported quarterly earnings of $2.26 per share, missing the Zacks Consensus Estimate of $2.3 per share, but showing an increase from $2.01 per share a year ago [1][2]. Financial Performance - The company posted revenues of $653 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.24% and showing a slight increase from $649.73 million year-over-year [3]. - The earnings surprise for the quarter was -1.74%, while the previous quarter saw a positive surprise of +35.23% with actual earnings of $2.61 compared to an expected $1.93 [2]. Market Performance - Bio-Rad shares have increased by approximately 0.6% since the beginning of the year, in contrast to the S&P 500's gain of 17.2% [4]. - The current Zacks Rank for Bio-Rad is 4 (Sell), indicating expectations of underperformance in the near future [7]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $2.57 on revenues of $693.11 million, and for the current fiscal year, it is $10.02 on revenues of $2.58 billion [8]. - The Medical - Products industry, to which Bio-Rad belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [9].

Antero Resources (AR) came out with quarterly earnings of $0.15 per share, missing the Zacks Consensus Estimate of $0.22 per share. This compares to a loss of $0.12 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -31.82%. A quarter ago, it was expected that this oil and natural gas producer would post earnings of $0.48 per share when it actually produced earnings of $0.35, delivering a surprise of -27.08%.Over the last four qu ...